Cidara Therapeutics Inc 2025年季度报告

FORM10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDEDMARCH31, 2025 ☐TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROMTOCommission file number:001-36912 CIDARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (Registrant’s Telephone Number, Including Area Code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section13 or 15(d) of the Securities Exchange Actof 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company.See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and"emerging growth company" in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of May5, 2025, the registrant had12,969,823shares of Common Stock ($0.0001 par value) outstanding. CIDARA THERAPEUTICS, INC. TABLE OF CONTENTS PART I. FINANCIAL INFORMATION Item1. Condensed Consolidated Financial Statements (unaudited)Condensed Consolidated Balance Sheets as of March 31, 2025 (unaudited) and December 31, 2024Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months endedMarch 31, 2025 and 2024 (unaudited)Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2025 and 2024(unaudited)Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders’Equity(Deficit) for the threemonths endedMarch 31, 2025and 2024(unaudited)Notes to Condensed Consolidated Financial Statements (unaudited)Item 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem3. Quantitative and Qualitative Disclosures about Market RiskItem4. Controls and ProceduresPART II. OTHER INFORMATIONItem1. Legal ProceedingsItem1A. Risk FactorsItem2. Unregistered Sales of Equity Securities and Use of ProceedsItem3. Defaults Upon Senior SecuritiesItem4. Mine Safety DisclosuresItem5. Other InformationItem6. ExhibitsSIGNATURES CIDARA THERAPEUTICS, INC.Condensed Consolidated Balance Sheets (unaudited) CIDARA THERAPEUTICS, INC.Condensed Consolidated Statements of Operations and Comprehensive Loss(unaudited) CIDARA THERAPEUTICS, INC.Condensed Consolidated Statements of Cash Flows(unaudited) CIDARA THERAPEUTICS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(unaudited) 1.THE COMPANY AND BASIS OF PRESENTATION Description of Business Cidara Therapeutics, Inc., or the Company, was originally incorporated in Delaware in December 2012 as K2 Therapeutics, Inc.,and its name was changed to Cidara Therapeutics, Inc. in July 2014. The Company is a biotechnology company using itsproprietary Cloudbreakplatform to develop drug-Fc conjugate, or DFC, therapeutics designed to save lives and improve thestandard of care for patients facing serious diseases. The Company’s proprietary Cloudbreak platform enables development ofnovel DFCs that inhibit specific disease targets while simultaneously engaging the immune system.® The Company’s most advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prophylaxis andtreatment of seasonal and pandemic influenza, which has completed Phase 1 and Phase 2a clinical trials under a partnershipwith J&J Innovative Medicine, previously Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies ofJohnson & Johnson, or Janssen. On April 23, 2024, the Company and Janssen entered into a license and technology transferagreement, or the Janssen License Agreement, under which the Company reacquired all rights for CD388 from Janssen todevelop and commercialize CD388. The Company is currently conducting a 5,041 subject, randomized, double-blind, controlled Phase 2b clinical trial, or theNAVIGATE study, evaluating the efficacy and safety